Clinical Trial Update: Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy [Phase 2, Phase 3]

View source ↗

Summary

An open-label safety study of Dipraglurant (ADX48621) in Parkinson's disease patients receiving levodopa-based therapy has been terminated (Phase 2/Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Drug-induced Dyskinesia
• Parkinson Disease

Drugs mentioned

• Dipraglurant (dipraglurant)

Snippet

Sponsor: Addex Pharma S.A. | Conditions: Parkinson Disease, Dyskinesia, Drug-Induced | Phase 2, Phase 3 | Status: TERMINATED